Gentium S.p.A. (GENT) announced that the medical team from the National University Corporation Hamamatsu University School of Medicine or HUSM, Fukushima Medical University or FMU have successfully administered defibrotide to the first subject in the phase 1 clinical study.
This Investigator led clinical trial aims "to evaluate the Safety and Pharmacokinetics of Defibrotide or DF in Healthy Adults."
The trial has been adopted as a Health and Labour Sciences Research Grant in 2012 for Practical Use of Medical Technology (categorized as a study project to support practical drug/medical device use during the reconstruction of disaster-hit areas in eastern Japan).
Gentium noted that it is providing defibrotide and technical support to HSUM.
For comments and feedback: editorial@rttnews.com